Takeda Pharmaceutical (NYSE:TAK) Stock Moved Down to Hold by Zacks Research

Zacks Research cut shares of Takeda Pharmaceutical (NYSE:TAK) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks reports.

Several other equities research analysts also recently commented on TAK. Weiss Ratings upgraded Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, September 11th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Performance

TAK stock opened at $17.87 on Thursday. The stock has a market capitalization of $57.25 billion, a PE ratio of 52.55 and a beta of -0.07. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $19.10. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock’s 50 day simple moving average is $18.06 and its 200 day simple moving average is $17.24.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, research analysts forecast that Takeda Pharmaceutical will post 1.56 earnings per share for the current fiscal year.

Insider Activity at Takeda Pharmaceutical

In related news, CEO Julie Kim sold 89,090 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $1,523,439.00. Following the completion of the transaction, the chief executive officer owned 391,489 shares of the company’s stock, valued at approximately $6,694,461.90. This represents a 18.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Anne Furney sold 30,868 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $527,842.80. Following the completion of the sale, the general counsel owned 204,298 shares of the company’s stock, valued at $3,493,495.80. The trade was a 13.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 627,457 shares of company stock worth $10,981,175 in the last 90 days. Company insiders own 0.04% of the company’s stock.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. Capital Research Global Investors raised its stake in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after purchasing an additional 82,643 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. Renaissance Technologies LLC grew its holdings in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after buying an additional 60,725 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder.